EVEREST MED Shares Climb Over 5% in Morning Session Following Patent Victory for Innovative IgA Nephropathy Drug

Stock News10:38

EVEREST MED (01952) saw its shares rise more than 5% during the morning trading session. At the time of writing, the stock was up 4.75%, trading at HK$35.7, with a turnover of HK$44.2498 million. The movement follows a recent company announcement regarding a key development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation behavioral preservation. The court ordered relevant generic drug manufacturers to immediately cease infringing activities and withdraw their products from listing platforms, with the ruling taking effect immediately. It was reported that in December 2025, Hainan Herui Pharmaceutical's generic version of budesonide enteric-coated capsules became the first to receive approval for market entry.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment